Please assess the completion status of the following clinical trial:

Trial Title: Assessing Tolerability of Avonex Intramuscular Injections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18 - 65 years of age;~* Confirmed diagnosis of Relapsing Remitting Multiple Sclerosis;~* Currently being treated with Avonex® for at least 90 days;~* Using 25 gauge needles for injection of Avonex® for at least 90 days;~* Willing and able to complete study questionnaires; and~* Provided informed consent to participate in this study~Exclusion Criteria:~* Diagnosis of Progressive Multiple Sclerosis;~* History of recent illness or infection;~* History of allergic reaction to Avonex®;~* Any prior usage of a 30 gauge needle for administration of Avonex®;~* Concurrent treatment with other immunomodulating therapies;~* Pregnant or planning on becoming pregnant;~* Nursing mothers; and~* Unable to complete the requirements of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 30 gauge (Type: EXPERIMENTAL): Subjects used a 30 gauge needle for intramuscular injection of Avonex.
- 25 gauge (Type: EXPERIMENTAL): Subjects used a 25 gauge needle for intramuscular injection of Avonex.

Based on this trial design, predict the completion outcome and termination type (if applicable).